Definitive Contract 75N92023C00002

The National Institutes of Health National Heart Lung and Blood Institute awarded a $15 million firm fixed price purchase order to National Collegiate Inventors & Innovators Alliance, Inc., doing business as Venturewell, for the Rapid Acceleration of Diagnostics (RADX) Initiative - Phase 0. As part of the RADX Initiative to accelerate the development, testing, and implementation of novel diagnostics for COVID-19, this contract will support Venturewell's efforts to advance diagnostics through...

This federal contract award was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to the National Collegiate Inventors & Innovators Alliance, Inc. (doing business as Venturewell), a non-profit organization based in Hadley, Massachusetts. The $2,097,064.03 firm fixed-price delivery order is for clinical evaluation services in support of the Rapid Acceleration of Diagnostics (RADx) initiative, which aims to...

The Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute awarded a $250,000 firm fixed price purchase order to Arete Biosciences, LLC of Chicago, Illinois. The contract is to support the Rapid Acceleration of Diagnostics (RADX) Program Technology effort through January 18, 2022. No major subcontractors or set aside designations were indicated. The award provides funding for Arete Biosciences to likely deliver diagnostic technologies or...

This is a definitive contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to the National Collegiate Inventors & Innovators Alliance, Inc. (doing business as Venturewell), a non-profit organization. The $33,379,628.30 firm fixed-price contract is for NHLBI's Rapid Acceleration of Diagnostics (RADx) initiative, providing ITAP consultants and infrastructure support. The contract has a period of...

This federal contract award, valued at $11,047,692.63, was issued by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to the National Collegiate Inventors & Innovators Alliance, Inc., doing business as Venturewell. The contract supports the NIBIB RAPID ACCELERATION OF DIAGNOSTICS (RADX) INITIATIVE - INFRASTRUCTURE SUPPORT, which aims to accelerate the development, validation, and commercialization of innovative COVID-19 and other...

The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded a firm fixed price purchase order contract to Ascella Biosystems Inc., a for-profit manufacturer, on January 13, 2021. The $250,000.00 contract is for RADX-TECH - SUPPORT SERVICES NEEDED FOR WORK PACKAGE 1 and is associated with the Coronavirus COVID-19 national interest action. The contract does not have a set-aside designation and is scheduled for completion on January...

This is a $13,712,443.95 firm fixed-price contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to National Collegiate Inventors & Innovators Alliance, Inc. (doing business as Venturewell), a non-profit organization based in Hadley, Massachusetts. The contract is for Venturewell to provide support for technical assessments and project management for the NHLBI's Rapid Acceleration of Diagnostics (RADx) initiative,...

The National Institutes of Health's National Heart, Lung and Blood Institute awarded an $18.2 million firm fixed price definitive contract to Quanterix Corporation as part of the Rapid Acceleration of Diagnostics initiative. The RADx program aims to expedite the development, commercialization, and implementation of Covid-19 testing technologies to significantly increase domestic testing capacity. Quanterix will support this objective through the delivery of diagnostic solutions over a two-year...

This federal contract award is for the Rapid Acceleration of Diagnostics (RADX) program, which is being led by the National Heart Lung and Blood Institute (NHLBI), a civilian agency. The $17,250,000.00 Firm Fixed Price contract was awarded to Talis Biomedical Corporation, a For Profit Organization and Manufacturer of Goods, to deliver a highly scalable SARS-CoV-2 RNA detection solution that can provide results in minutes. This definitive contract does not have a set-aside designation and has a...

The National Institutes of Health's National Heart, Lung and Blood Institute awarded Lumiradx, Inc. a $243,000 firm fixed-price purchase order to finalize development of its SARS-CoV-2 and influenza A/B test. As the prime contractor, Lumiradx will deliver its LumiraDx Platform test to the NIH for use in detecting the viruses that cause COVID-19 and seasonal flu. No subcontractors or set-aside designations were identified. This purchase order supports the NIH's ongoing efforts to expand...